Otis Brawley, MD, presenting at the 2016 Annual Meeting of American Society of Clinical Oncology (ASCO) on Monday June 6, 2016.

The latest chapter in Otis W. Brawley, MD’s illustrious career in cancer prevention and control commenced earlier this month when he began his tenure as a Bloomberg Distinguished Professor at Johns Hopkins University in Baltimore.

During an exclusive interview with Onco’Zine, Brawley, 59, followed up on his promise in November to share information about what he then termed as a “tremendous opportunity to increase my impact in health disparities and cancer screening and how health care is applied.”

He told me that his appointment at Hopkins would also mean that he would be spending more time working on public policy issues down the road in Washington, DC, and he emphatically proclaimed that the position would afford him “more freedom to speak and academic independence.”

In November, Brawley, a medical oncologist and leading expert in cancer prevention and control, resigned after serving as chief medical and scientific officer and executive vice president with the national American Cancer Society for 11 years.

Photo 1.0: Gilman Hall, at Johns Hopkins University, in Baltimore, Maryland. Photo Courtesy: © 2008 Daderot.
Photo 1.0: Gilman Hall, at Johns Hopkins University, in Baltimore, Maryland. Photo Courtesy: © 2008 Daderot.

He did not go into detail at that time about the circumstances related to the timing of his departure, but told me during our recent telephone interview that Hopkins began recruiting him as a Bloomberg Distinguished Professor in February 2018.

Advertisement #3

Bloomberg Professorship
The Bloomberg program was established in 2015 with a $350 million gift from philanthropist and former New York City Mayor Michael R. Bloomberg, who is a Hopkins graduate.

Brawley is the 39th recipient of the title, which will ultimately be held by a total of 50 scholars charged with addressing major world problems and teaching the next generation of physicians, scientists, and academics.

He will lead an interdisciplinary research effort focused on reducing racial, economic, and social disparities in preventing, detecting, and treating cancer in the United States and globally, and have appointments at both Hopkins’ Bloomberg School of Public Health and its Sidney Kimmel Comprehensive Cancer Center.

He will also serve as the Kimmel Cancer Center’s associate director for community outreach and engagement, directing community outreach programs for underserved populations throughout Maryland and Washington DC.

Brawley said that he also plans to continue his clinical activities at the cancer center, and will teach cancer epidemiology to both undergraduate and graduate students in the school of public health as well as teach in the medical school.

Why Hopkins?
“This is really a fabulous job and will allow me to work day in and day out? with the many amazing? people I’ve respected who are already doing community outreach at Hopkins,” he said, noting that he had been able to collaborate with many of them in the past during his time with the American Cancer Society.

“And one of the biggest attractions at Hopkins is its spectacular faculty and amazing students, and the opportunity to help shape the next generation of cancer prevention and control scientists,” he said.

The Bloomberg professorship will allow Brawley to merge all of his professional passions in an unfettered capacity.

“I tend to be a magnet for attention,” he admitted, “and cancer prevention and disparities are areas that need attention.”

After spending his early career at the National Cancer Institute?s division of cancer prevention, he left for Atlanta in 2001 to become deputy director for cancer control at Emory’s Winship Cancer Institute and medical director of Grady Memorial Hospital’s cancer center, before joining American Cancer Society in 2007 as its chief medical and scientific officer.

Thomas Kornberg, Ph.D, Otis W. Brawley, MD and Richard L. White, MD, FACS discuss issues during the General Session X: Health Policy: Opportunities and Challenges at the Breast Cancer Symposium, supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology, ASBS American Society of Breast Surgeons and ASBC American Society of Breast Cancer.
Photo 1:0 Thomas Kornberg, Ph.D, Otis W. Brawley, MD and Richard L. White, MD, FACS discuss issues during the General Session X: Health Policy: Opportunities and Challenges at the Breast Cancer Symposium, supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology, ASBS American Society of Breast Surgeons and ASBC American Society of Breast Cancer.

“I’ve spent time in government service, working for a foundation, and now I?m back in academia, and although I haven?t worked in industry, I have had experience in drug development.”

“I’ve had the opportunity to be a cancer center director at several places, and to run institutes that look at health outcomes and disparities, and of all those choices, I chose this,” he explained.

Rational Medicine
Brawley has long been a critic of over-screening, over-diagnosis, and over-treatment in cancer, and has been a vocal proponent of what he calls “rational medicine.”

“I don’t mean rationing medicine, but applying what we already know about cancer in a rational way.

He said that with today’s high costs of health care and the unnecessary use of many medical interventions, he intends to continue to be a ?thought leader? in cancer control, to focus on affecting behavior in the community, and to encourage good science and the application of good science.

Future Testimony
And in addition to helping educate the public and medical practitioners about rational medicine and the need for increased cancer prevention, he intends to take this message to Congress.

Brawley said the he has testified numerous times before Congress in the past and is being encouraged by Hopkins to continue appearing before and appealing to legislators about cancer prevention and disparity issues.

In an episode of The Onco?Zine Brief (Meeting the Challenge of Attacking Cancer from Every Angle) Peter Hofland, Ph.D and Sonia Portillo talk with Otis Brawley, MD, MACP the Chief Medical and Scientific Officer of the American Cancer Society. Hofland and Portillo ask Brawley about the past, present, and future of the fight against cancer, including screening, diagnostics and treatment with novel, targeted drugs, and the role of the American Cancer Society in helping to prevent cancer. In this interview they further address some of the most pressing issues in oncology today, such as cancer health disparities and access to healthcare in lower income areas, as well implementing healthy lifestyle choices and reducing cancer risk factors, in order to make the biggest impact possible on reducing the number of cancer-related deaths. Hofland and Portillo also ask Brawley how to go about meeting the challenges in healthcare and find a solution for cancer health disparities, as well as how to educate the public on how to prevent and reduce risks of cancer in our daily lives – including the need of a healthy diet and to stop smoking. This interview, took place during the annual meeting of the American Association of Cancer Research held April 14-18th, 2018, in Chicago, Illinois. Click here to listen to the program.

“American culture is more focused on individuals than group dynamics, and one lesson I learned during many congressional testimonies was that congressmen aren?t interested in population statistics and rates, but anecdotes,” he said, adding that this makes it especially important to increase understanding about population medicine and epidemiology, not only to the public and Congress, but to doctors as well, and to get them to understand that prevention and control can reduce cancer risk.

To Brawley, disparities exist when human beings do not receive the same health care that other human beings receive.

One example he cited was a study he had done several years ago in Atlanta that showed that 7% of black women and 3% of white women who had heard messages about getting mammograms and were diagnosed with early stage breast cancer did not receive any treatment during their first year of diagnosis.

He said that while at American Cancer Society he and his team started interventions to encourage people to carry through with their treatment that included navigation programs, and community education and outreach regarding health behaviors. He added that some of these programs were based on anti-smoking initiatives.

Other examples of a health disparities include:

  • a study that showed from 1988 to 2015, eight states had a 44%-51% decrease in breast cancer mortality, while during the same period another nine states only had a 20% to 29% decrease;
  • and a study that showed the risk of dying from cancer in 2015 in Utah was 125 deaths for every 100,000 people while in Kentucky that risk was 195 for every 100,000 people.

Brawley noted that disparities can also exist in affluent communities where some people with health insurance may be subject to over-screening, over-diagnosis, and over-treatment for breast or prostate cancer resulting in the “misapplication of a lot of technologies that we have that can lead to huge disparities and increased costs?while these individuals may not have been told to exercise and watch their diets.”

He also said that health care costs in the U.S. are about twice as much as many European nations with outcomes that are no better.

21st Century Vision
Brawley’s vision of a 21st century NCI-designated cancer center involves having centers serving the communities in which they are located.

“Not just by providing health care, but also by being active in defining what are the problems in the communities that are served, and educating those communities to be healthy and about cancer prevention. For instance,” he added, “obesity has become a bigger cause of cancer than tobacco in many United States communities, and many “people don’t realize this.”

Born in Detroit, Brawley received both his undergraduate and medical degrees at the University of Chicago, and did his internal medicine training at Cleveland’s Case Western Reserve and medical oncology fellowship at the National Cancer Institute.

He was elected to the National Academy of Medicine (formerly the Institute of Medicine) in recognition of his expertise in cancer prevention and control in 2015, and was recently named to the NCI?s Board of Scientific Advisors.

With Paul Goldberg he co-authored How We Do Harm — A Doctor Breaks Ranks About Being Sick in America, published by St. Martin’s Press in 2011, and last July he and colleagues at ACS published “An Assessment of Progress in Cancer Control in CA: A Cancer Journal for Clinicians.”

Brawley is now hoping that his new Bloomberg-based bully pulpit will help him continue to propel the importance of prevention and reducing disparities with the freedom to pursue a scientific agenda free of any other agenda.

This is the first installment of a series of new beginnings for distinguished members of the cancer community.

Last Editorial Review: January 23, 2019

Featured Image: Otis W. Brawley, MD, presenting during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) being held at the McCormick Place convention center in Chicago, Illinois, on Monday, June 6, 2016. Courtesy: © 2010 – 2019 ASCO/Zach Boyden-Holmes. Used with permission. Photo 1.0: Gilman Hall, at Johns Hopkins University, in Baltimore, Maryland. Courtesy: © 2010 – 2019 Fotolia. Used with permission. Photo 2.0: Thomas Kornberg, Ph.D, Otis W. Brawley, MD and Richard L. White, MD, FACS discuss issues during the General Session X: Health Policy: Opportunities and Challenges at the Breast Cancer Symposium, supported by ASCO, the American Society of Clinical Oncology, ASTRO, The American Society of Radiation Oncology, SSO, Society of Surgical Oncology, ASBS American Society of Breast Surgeons and ASBC American Society of Breast Cancer. Courtesy: © 2010 – 2019 ASCO/Todd Buchanan. Used with permission.

Copyright © 2010 – 2019 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine, Oncozine and The Onco’Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.

Advertisement #5
Previous articleStudy Shows How Molecular Profiling may Help Catch Lung Cancer Early, Leading to New Treatments
Next articleMinimally Invasive Endoscopy Tool may Change Treatment for Pancreatic Cancer Patients
Eric T. Rosenthal is an independent medical journalist specializing in providing insight, perspective, and transparency into various issues, trends, and controversies in oncology, and other areas concerning the politics of health care. He is currently editor-at-large with ADC Review | Journal of Antibody-drug Conjugates and Onco?Zine, special correspondent for MedPage Today, and a contributor to The Hill. Rosenthal was formerly special correspondent for Oncology Times, and senior correspondent and news director for Vital Option International?s nationally syndicated The Group Room cancer talk-radio show. Rosenthal?s reporting is known for its balance providing perspective and context, and taking readers behind the scenes by exploring the ?how? and ?why.?? This is evidenced in his series ?Eric Rosenthal Reports,? which, in June 2017, returned to Onco?Zine. He also co-authors Op-Eds and develops forums for health care-related issues with Nancy G. Brinker, founder of Susan G. Komen, former U.S. State Department Chief of Protocol, Ambassador to Hungary and former U.N. World Health Organization?s Goodwill Ambassador for Cancer Control. Rosenthal?s work has also appeared in the Journal of the National Cancer Institute, Courage magazine, and elsewhere, and he wrote a series of guest posts for PBS/WETA-TV?s cancerfilms.org ?Producers? Blog? in 2015. He founded EvocaTalk? Research & Reports in 2002 as a service that identifies, explores, and helps resolve issues, and enhances insights through interactive interviews and analysis in both individual and group settings. After beginning his journalism career at the Trenton Times in 1972, where he received a state journalism award for a magazine cover story on schizophrenia research, Rosenthal served in a number of academic public affairs positions before returning to full-time journalism in 1998. These included: editor of publications and public affairs at the Franklin Institute; public relations director at Drexel University; news bureau manager for the American College of Physicians and its Annals of Internal Medicine; and public affairs director at Fox Chase Cancer Center, during which time he founded the National Cancer Institute (NCI)-Designated Cancer Centers Public Affairs Network in 1990. He was named press officer for the American Society of Clinical Oncology?s annual meeting in 1990, and has served on numerous national committees, including the NCI Director?s Consumer Liaison Group, the NCI External Work Group for the Cancer Progress Report, the Oncology Nursing Society?s Consumer Advocacy Panel, and as journalist member of Ken Burns? Cancer: Emperor of All Maladies PBS Documentary Educational Subcommittee. He helped organize two national conferences focusing on the medical-news dissemination process at Cold Spring Harbor Laboratory and the Mayo Clinic; is an global health adviser for Concordia and served as co-chair its Concordia Summit global cancer research collaboration session in 2016 and its cancer burden in Latin America conference in 2017; and practices ?3-D journalism? by organizing and moderating panels and conferences to further develop issues he has covered as a journalist. orcid.org/0000-0001-6778-0791